Despite the increasing use and success of interventional coronary reperfusion strategies,
morbidity and mortality from acute myocardial infarction are still substantial. Myocardial …

Acute myocardial infarction (AMI) and the heart failure (HF) which may follow are among the
leading causes of death and disability worldwide. As such, new therapeutic interventions are …

In contrast to nitric oxide, which has well established and important roles in the regulation of
blood flow and thrombosis, neurotransmission, the normal functioning of the genitourinary …

Ischaemic heart disease and the heart failure that often results, remain the leading causes of
death and disability in Europe and worldwide. As such, in order to prevent heart failure and …

The translation from numerous successful animal experiments on cardioprotection beyond
that by reperfusion to clinical practice has to date been disappointing. Animal experiments …

Ischaemic heart disease (IHD) remains the leading cause of death and disability in Europe
and worldwide. A major cause of morbidity and mortality in IHD patients is an acute ST …

Acute myocardial infarction (AMI) and the heart failure that often follows, are major causes of
death and disability worldwide. As such, new therapies are required to limit myocardial …

Rationale: Despite 4 decades of intense effort and substantial financial investment, the
cardioprotection field has failed to deliver a single drug that effectively reduces myocardial …

Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide.
As a result, novel therapies are still needed to protect the heart from the detrimental effects of …

Mitochondrial transplantation is a therapeutic approach developed by McCully and
colleagues that entails the injection of healthy mitochondria harvested from unaffected tissue …